AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.
By Tim Fernholz
Published on April 22, 2026.
10x Science, a startup founded in 2025, has announced a $4.8 million seed round led by Initialized Capital and with backing from Y Combinator, Civilization Ventures, and Founder Factor. The company aims to identify more potential drugs through characterizing them for testing and mass production. The founders, David Roberts and Andrew Reiter, and Vishnu Tejas, are experienced biochemists and experts in computer science and AI models. They used a deep learning model developed by Google's DeepMind to predict complex protein structures. The platform combines deterministic algorithms rooted in chemistry and biology with AI agents to interpret the data. The most accurate way to assess molecules is through mass spectrometry, a technique that can determine their atomic structure by measuring them in an electric field. Matthew Crawford, scientist at Rilas Technologies, has been using the 10x Science platform for several weeks and says it is speeding up his work.
Related Articles
The grim warning sign from AI influencers that keep racking up comments from lonely men: ‘Societal loss of humanity’
AI influencers, often posing as real-life celebrities, are posing as AI-coded models to lure lonely men, warning of societal loss of humanity.
Why 'It’s Not Personal, It’s Business' Is One of Leadership’s Biggest Lies
The phrase "it's not personal" is misleading, harmful to business, and often mischaracterized, particularly in the context of race controversies.
How Gen Z is helping to drive a digital detox boom
The digital detox movement, driven by grassroots efforts and a growing awareness of screen time, is gaining momentum in the US, with activities like phone-free bars and restaurants.